University of Ghent

Vib Vzw

Oxyrane UK Limited

Vlaams Interuniversitair Institute Voor Biotechnologie Vzw

Research Corporation Technologies, Inc.

Steven Geysens

Nico L M Callewaert

Leander Meuris

Karen De Pourcq

Roland Henri Contreras

Wouter Vervecken

Nico Callewaert

Nico L Callewaert

The disclosure relates to the field of glyco-engineering, more specifically, to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells are glyco-engineered yeast cells in which, additionally, at least one exogenous enzyme needed for complex glycosylation is present, e.g., allowing easier separation of differentially glycosylated glycoproteins.

Cells producing glycoproteins having altered glycosylation patterns and method and use thereof

The present invention provides new forms of human &#x3b1;-N-acetylgalactosaminidase (NAGAL) polypeptide or a functionally active variant or fragment thereof, nucleic acids encoding the same, and related products and uses, including use in methods of treating Fabry disease, Schindler disease or Kanzaki disease.

Human alpha-N-acetylgalactosaminidase polypeptide

The present application relates to the field of glyco-engineering, more specifically to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells and methods are glyco-engineered yeast cells in which additionally at least one exogenous enzyme needed for complex glycosylation is present, e.g. allowing easier separation of differentially glycosylated glycoproteins.

The present invention relates to the use of a glucosidase II mutation to increase protein secretion in eukaryotic cells. The present invention relates further to the use of eukaryotic cells, comprising a mutant glucosidase II gene, possibly in combination with the expression of a recombinant &#x3b1;-1,2-mannosidase gene and/or a recombinant N-acetylglucosaminyl-transferase gene, as a host for protein secretion.

Protein secretion in eukaryotic cells

Growing community of inventors

Wannegem-Lede, Belgium

Steven Geysens